About the Test We Offer

Elecsys®Anti-SARS-CoV-2 test by roche diagnostics

Abrishami Dermatopathology is enhancing the services it offers to help address the COVID-19 pandemic with the addition of the Elecsys® Anti-SARS-CoV-2 test from Roche Diagnostics. This is a highly accurate antibody test for the novel coronavirus which received Emergency Use Authorization from the FDA in May 2020.

The Elecsys®Anti-SARS-CoV-2 test is designed to help healthcare professionals determine if a patient has been exposed to the SARS-CoV-2 virus and has developed antibodies against it. The test, manufactured by Roche Diagnostics, was made available recently under Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) and has 100% sensitivity and 99.8% specificity.

The Elecsys® Anti-SARS-CoV-2 assay is uniquely designed to identify mature (high affinity) IgM and IgG antibodies developed late in the immune response, significantly reducing the chance of a false positive result. It provides 99.8 percent specificity, which is superior to previously available antibody tests. This specificity is crucial to determine reliably if a person has been exposed to the virus and has developed antibodies. Tests with lower specificity and sensitivity can lead to a high number of misidentified cases in a population. A false positive result may put a patient at risk by indicating they have antibodies when they do not. The test runs on the Cobas-e analyzer, and these fully automated systems can provide SARS-Cov-2 test results in 18 minutes for one test, with a test throughput of up to 100 tests/hour on a Roche analyzer.

Please use buttons below to inquire re routing, supplies and subscription model: